Major Depressive Disorder

Major depressive disorder is a medical condition defined by at least two weeks of depressed mood or loss of interest in nearly everything, combined with changes in sleep, appetite, energy, concentration, self-worth, or thoughts of death. The DSM-5 requires five or more of those symptoms most of the day, nearly every day, causing real impairment in work, school, relationships, or self-care.

It is not the same as sadness after a hard week, and it is not the same as grief. Grief comes in waves around a specific loss, self-esteem usually stays intact, and the pain coexists with moments of connection. MDD is flatter and more global: hopelessness about everything, anhedonia (nothing feels good, including things that used to), and a sense that the body itself has slowed. It can be triggered by a loss or stressor but does not resolve when circumstances improve, and it responds to specific treatments (psychotherapy, antidepressants, or both) the way grief does not.

DSM-5 diagnostic symptoms of MDD, with notes on how they tend to present in Black patients:

• Depressed, empty, or hopeless mood most of the day. In Black men often described as numb, stuck, frustrated, or angry rather than sad.
• Loss of interest or pleasure in almost everything (anhedonia). "Nothing hits the same."
• Significant change in appetite or weight, up or down, without dieting.
• Insomnia or hypersomnia. Sleeping four hours and lying awake, or sleeping ten and waking unrefreshed.
• Psychomotor agitation or slowing visible to other people.
• Fatigue or loss of energy nearly every day. Frequently the chief complaint that brings Black patients to primary care.
• Feelings of worthlessness or excessive, inappropriate guilt.
• Difficulty concentrating, thinking, or making decisions; work performance slipping, zoning out mid-conversation.
• Recurrent thoughts of death, suicidal ideation, a suicide plan, or a suicide attempt.
• Somatic complaints without a clear medical explanation: chronic back pain, headaches, GI distress, palpitations, jaw or chest tightness.
• Irritability, social withdrawal, or increased substance use, especially in Black men and adolescents, frequently misread as a behavior problem rather than depression.

The U.S. Preventive Services Task Force gave depression screening in all adults, including pregnant and postpartum patients and older adults, a Grade B recommendation in its 2023 update (USPSTF, JAMA, 2023). Grade B means moderate certainty of moderate net benefit, and insurers must cover it without cost-sharing under the ACA.

Primary-care offices typically use the PHQ-2 first: two questions about depressed mood and anhedonia over the prior two weeks, scored 0 to 6. A score of 3 or higher triggers the full PHQ-9, a 9-item self-report covering DSM-5 criteria over the same window. PHQ-9 cut-points are 5 (mild), 10 (moderate), 15 (moderately severe), and 20 (severe); item 9 specifically screens for suicidal ideation.

The caveat for Black patients: every PHQ-9 item showed statistically significant differential item functioning in Black adults compared to other racial groups, with small effect sizes (Harry et al., Journal of Affective Disorders, 2023). The PHQ-9 is not broken, but a low score in a Black patient with prominent somatic, irritable, or anhedonic features is not a clean negative. If your PHQ-9 came back "normal" and you still feel the way you feel, say so out loud.

The 2019 American Psychological Association clinical practice guideline for depression in adults recommends second-generation antidepressants (SSRIs, SNRIs), cognitive behavioral therapy (CBT), and interpersonal psychotherapy (IPT) as first-line monotherapies, with combination therapy recommended over either alone for moderate-to-severe depression.

CBT targets the thought-behavior-mood loop; IPT targets depression in the context of relationships, roles, and losses. Both are time-limited (typically 12 to 20 sessions) and both have evidence in Black patients, though Black participants have historically been underrepresented in the foundational trials. SSRIs (sertraline, escitalopram, fluoxetine, citalopram) are usually tried first for tolerability; SNRIs (venlafaxine, duloxetine) are second-line or used when pain is prominent. Response rates in general adult populations sit around 30 to 45 percent for any single SSRI trial, and dedicated SSRI efficacy data in Black patients are limited, a gap the field has acknowledged for decades. CYP2D6 metabolizer variation differs by ancestry, including the CYP2D6*17 allele more common in people of African ancestry and associated with reduced enzyme activity (Bradford, Pharmacogenomics, 2002). Pharmacogenomic testing is not yet standard but is reasonable to ask about after two failed trials or unusual side effects.

Collaborative care, where primary care, a behavioral-health care manager, and a consulting psychiatrist coordinate around the patient, has the strongest system-level evidence for reducing the Black-white gap in depression outcomes and is worth asking for by name. ECT, transcranial magnetic stimulation, and ketamine/esketamine are options for treatment-resistant cases.